Last reviewed · How we verify
Psoriatic Arthritis
Approved treatments
- Cosentyx · Janssen Research & Development, LLC
- In open-label phase: treatment with tofacitinib · Pfizer
- tumor necrosis factor inhibitors (TNFi) · Pfizer
- Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Tasocitinib · Pfizer
- Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - TNF Inhibitor · Pfizer
- Cosentyx · Novartis
Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor. - Cimzia · UCB
Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity. - CYLTEZO · BOEHRINGER INGELHEIM
- Taltz · Yale University
- Xeljanz · Pfizer
Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs. - Anti-Beta Interferon (PF-06823859) · Pfizer
- Taltz · Eli Lilly
Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor. - Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions. - Skyrizi · AbbVie
Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response. - Intra-articular corticosteroid injections · Pfizer
- Xeljanz · Pfizer
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Cimzia · University of Washington
- Humira · Sohag University
- TOFA
Clinical guidelines
- FDA label — 2L
XELJANZ (tablets and oral solution) is indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ XR (extended-release tablets) is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
XELJANZ (tablets and oral solution) is indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ XR (extended-release tablets) is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
XELJANZ (tablets and oral solution) is indicated for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 1L|2L
Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. - FDA label — 2L
reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. - FDA label — 1L
TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis. - FDA label — 1L
TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis. - FDA label — 1L
TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. - FDA label — 1L|2L
Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. - FDA label — 1L
Secukinumab is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 2 years of age and older. - FDA label — 1L
Secukinumab is indicated for the treatment of active enthesitis-related arthritis in pediatric patients 4 years of age and older. - FDA label — 2L
XELJANZ (tablets and oral solution) is indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ XR (extended-release tablets) is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
XELJANZ (tablets and oral solution) is indicated for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
RINVOQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 2L
RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: